Daniel M. Hartung, PharmD, MPH
Articles
May 17th 2024
Budget Impact Analysis of Biosimilar Natalizumab in the US
Edward Li, PharmD, MPH Adrian Goh, MEc Soni Gupta, MEc Marion Schauf, Dipl-Kff Anna Chen, PharmD, MS Daniel M. Hartung, PharmD, MPH
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
May 17th 2023
Chronic Overlapping Pain Conditions and Long-term Opioid Treatment
Maria Ukhanova, MD, PhD Robert W. Voss, MS Miguel Marino, PhD Nathalie Huguet, PhD Steffani R. Bailey, PhD Daniel M. Hartung, PharmD, MPH Jean O’Malley, MPH Irina Chamine, PhD John Muench, MD, MPH
Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.
Latest Updated Articles
Published: August 18th 2025 | Updated: August 25th 2025
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 19th 2025 | Updated: August 22nd 2025
Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: June 6th 2025 | Updated: August 18th 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
